The overall objective of this research is to characterize the structural mechanisms by which cancer mutations deregulate the retinoblastoma tumor suppressor protein (Rb). Rb is a multifunctional hub protein that facilitates protein-protein interactions in order to carry out various functions related to cell growth and chromatin regulation. Recent cancer genome sequencing data have highlighted sites of recurrent somatic and germline missense mutations, the majority of which occur to the highly-conserved pocket domain. A detailed molecular understanding of the direct structural and functional consequences of these mutations is key to parsing the mechanisms by which Rb deregulation occurs in cancers, as well as a first step toward identifying strategies to therapeutically restore loss of Rb function in cancer patients. The overall objective of this research will be achieved through two aims, which together will generate complete structure-function profiles for each of the 59 recurrent clinical missense mutations to the pocket domain of Rb. The goal of Aim 1 is to study Rb mutants as purified proteins in biochemical assays that characterize which protein-binding functions are perturbed by which mutations. To achieve this goal, a differential scanning fluorimetry (DSF) assay has been developed for use with Rb and protein interaction partners, which diagnoses changes to fold stability and protein-protein interactions that arise as a consequence of mutations. These assays will be further supported by data generated using fluorescence polarization (FP), isothermal titration calorimetry (ITC), and differential scanning calorimetry (DSC). Together, multiple biophysical parameters will be measured for each mutant; including, protein melting temperatures, Gibbs free energy of unfolding, and dissociation constants for multiple protein binding partners. The goal of Aim 2 is to reveal the structural basis of cancer mutations to Rb using protein x-ray crystallography. The hypothesis is that the mutations deregulate Rb through various structural mechanisms, including: the direct disruption of critical protein binding interfaces, negative allosteric regulation of protein binding interfaces, and overall changes to the stability of the pocket domain fold. A thorough understanding of the structural aspects underpinning the mechanisms by which mutations deregulate Rb will provide a solid basis for rational approaches to restore its function.
Inactivation of the retinoblastoma tumor suppressor protein (Rb) is a common event in many types of cancers, yet to-date there have been no therapeutics developed that target Rb for the treatment of cancer. This research will identify structural and biochemical mechanisms of Rb inactivation that result from clinical recurrent missense mutations. Results of this research which will inform on functional outcomes of clinical mutations and provide high quality models to enable strategies to restore the loss of Rb function in cancer patients.
